Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial

Trial Profile

Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Oxymorphone (Primary) ; Dextropropoxyphene/paracetamol
  • Indications Intermittent claudication; Pain
  • Focus Therapeutic Use
  • Acronyms LUSTOR-II
  • Most Recent Events

    • 24 Feb 2016 According to ClinicalTrials.gov record, the treatment table has been amended from 2 to 6 arms for assignment of subjects to one of six different treatment sequences
    • 24 Feb 2016 Status changed from completed to discontinued due to removal of Darvocet from US market, according to ClinicalTrials.gov record.
    • 05 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top